572 related articles for article (PubMed ID: 18196999)
1. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
2. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer.
Ye B; Gagnon A; Mok SC
Expert Rev Proteomics; 2007 Feb; 4(1):121-31. PubMed ID: 17288520
[TBL] [Abstract][Full Text] [Related]
3. Proteomics and biomarkers for ovarian cancer diagnosis.
Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
[TBL] [Abstract][Full Text] [Related]
4. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
6. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
Jurisicova A; Jurisica I; Kislinger T
Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
[TBL] [Abstract][Full Text] [Related]
7. HE4 in ovarian cancer: from discovery to clinical application.
Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
[TBL] [Abstract][Full Text] [Related]
8. Current clinical use of biomarkers for epithelial ovarian cancer.
Moore RG; Maclaughlan S
Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
[TBL] [Abstract][Full Text] [Related]
11. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
12. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for lung cancer: clinical uses.
Greenberg AK; Lee MS
Curr Opin Pulm Med; 2007 Jul; 13(4):249-55. PubMed ID: 17534168
[TBL] [Abstract][Full Text] [Related]
14. New circulating biomarkers for prostate cancer.
Bensalah K; Lotan Y; Karam JA; Shariat SF
Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
16. Multiple biomarker panels for early detection of ovarian cancer.
Yurkovetsky ZR; Linkov FY; E Malehorn D; Lokshin AE
Future Oncol; 2006 Dec; 2(6):733-41. PubMed ID: 17155900
[TBL] [Abstract][Full Text] [Related]
17. [Biomarker in gynecologic malignancies].
Isonishi S
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576
[TBL] [Abstract][Full Text] [Related]
18. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer.
Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS
Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176
[TBL] [Abstract][Full Text] [Related]
19. An overview of biomarkers for the ovarian cancer diagnosis.
Zhang B; Cai FF; Zhong XY
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171
[TBL] [Abstract][Full Text] [Related]
20. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
